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1. Introduction 
Metastatic prostate tumours are responsible for the majority of deaths associated with 
prostate cancer. The most frequent site of prostate cancer metastasis is to bone; over 80% of 
men who die of the disease have metastatic bony lesions (Bubendorf et al., 2000). Early 
detection of prostate cancer remains crucial to effective treatment. However, we are still 
unable to identify with certainty those tumours requiring aggressive and immediate 
interventions, which are associated with considerable morbidity, from those where a 
“watchful waiting” approach may be more appropriate. Currently little is known about 
inherited determinants of an individual’s propensity to develop tumours that rapidly 
progress and metastasise (Hunter, 2006). Experimental evidence investigating the role of 
integrins in tumourigenesis suggests that they play important roles in tumour progression 
and metastasis, particularly the development of metastatic lesions in bone. Notably, recent 
evidence indicates that genetic variants in selected integrins influence risk and/or prostate 
tumour behaviour. 
The integrins represent a large family of cell surface receptors that are responsible for cell to 
cell adhesion and complex formation with ligands found within the extracellular matrix 
(ECM). The integrins have important roles in cell proliferation, cell survival, differentiation 
and cell migration. Thus, these adhesion receptors play important roles in many 
physiological processes including normal organ development and wound healing. Integrins 
are obligate, noncovalent, heterodimeric molecules, composed of a larger α subunit and a 
smaller β subunit. Each of the subunits extends from within the cytoplasm into the ECM. 
The ECM tail of the α and β subunits are approximately 700-1000 amino acid residues in 
length, and the cell membrane is spanned by approximately 20-24 residues. Integrin 
subunits have a short cytoplasmic tail, approximately 15-58 residues in length, with the 
exception of β4 which has a cytoplasmic tail approximately 1000 residues (Alghisi and 
Ruegg, 2006). Within the cytosol they are attached to the cytoskeleton via talin-actin 
microfilaments. A detailed review on integrin structure can be found in the following 
publications (Buckley et al., 1999; Humphries et al., 2003; Ivaska and Heino, 2000; Lu et al., 
2008). The conservation of integrin structure from more primitive through to higher order 
organisms highlights their importance to multicellular organisms (Burke, 1999). Upon 
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binding to extracellular ligands, the integrin molecules cluster at the membrane, permitting 
a focal cellular response and the transduction of signals from the ECM. Further, integrins 
respond to intracellular signalling resulting in conformational changes to the integrin 
molecules on the surface of cells, thus permitting modification of interactions with the ECM. 
Integrin signalling thus permits cells to be exquisitely sensitive to both extracellular 
(“outside-in”) and intracellular (“inside-out”) signalling (Burridge et al., 1988). 
To date, 24 heterodimers have been identified, derived from 18 α and eight β subunits. 
Additional variation is provided by subunit ‘variants’ created by alternate mRNA splicing 
events. Selected integrins can also form multiple heterodimers; for example, αv, β2 and β1 all 
form multiple αβ heterodimers (5, 4 and 12 respectively). Most, however, only form one or 
two heterodimers (Ivaska and Heino, 2000). There is promiscuity in integrin-ligand binding 
which may reflect the need to initiate different cellular processes using the same available 
ECM proteins. The ability of integrins to bind to multiple ligands is thought to be an 
advantage when elicitation of the response is more important than the ECM protein 
signalling it; for example, in cell migration and wound healing (Alghisi and Ruegg, 2006). 
The interaction of integrins with these ligands appears to be dependent upon signal 
transduction via the cytoplasmic tails to the ECM which is evoked by the focal adhesion 
kinase (FAK) pathway, although the exact mechanism regulating this process remains 
unclear. It is not surprising, then, that attempts to understand the mechanisms that underlie 
cell motility and adhesion have implicated the membrane spanning integrins as major 
regulatory molecules. Cell migration and motility are crucial to maintain and promote 
healthy cell development, wound healing and immunity. They are complex processes 
requiring tightly regulated and coordinated intra-cellular signal transduction with the ECM. 
Instances where uncontrolled cell adhesion and motility remain unchecked can lead to 
tumourigenesis and metastases (Wehrle-Haller and Imhof, 2003). 
Given the physiological functions of integrins, it is not surprising that the role of integrins in 
neoplasms has been of intense interest over the past decade. Most pertinent to tumour 
development is the role of integrins in cellular processes, including cell survival and 
proliferation, cell migration, angiogenesis and lymphangiogenesis. Integrins are now known 
to play a key role in tumour biology and are implicated in tumour initiation, progression 
and metastasis. Aberrant expression of integrins also has been demonstrated to play a key 
role in cancer survival and proliferation. Integrins physically interact with the actin 
cytoskeleton which provides the traction required for migration to occur (Vicente-
Manzanares et al., 2009). Integrin mediated matrix metalloproteinase (MMP) feedback 
systems control the degradation of ECM proteins. Importantly integrins play an important 
role in regulation of neovascularisation, required for metastases via the vascular endothelial 
growth factor (VEGF) pathway. 
Much work has focussed on profiling changes in the expression of integrins at different 
stages of tumour development. In normal prostate tissue, integrins are expressed by normal 
basal epithelial cells, permitting interaction with the basal lamina comprising collagens, 
laminins, fibronectin, vitronectin and tenascin. During prostate tumour development, many 
studies report the overall down-regulation of both α and β integrin subunits. However, 
prostate tumourigenesis proceeds through defined stages of development from prostatic 
intraepithelial neoplasia (PIN), high-grade PIN lesions, prostate confined tumour, invasive 
tumour and finally to androgen-independent tumours. More rigorous examination of the 
integrin profiles at different stages of tumour development has revealed a more complex 
expression profile (Goel et al., 2008). Much research effort has focused on the identification 
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of an integrin expression profile as a prognostic marker for prostate cancer. In particular, 
integrins from the αv group and in particular αvβ3 have been previously identified as a 
putative prognostic marker for a number of cancers including prostate cancer and its utility 
as a therapeutic target is under clinical trial (Beekman et al., 2006; Chen et al., 2008; McNeel 
et al., 2005). It is beyond the scope of this review to provide a detailed analysis of the role of 
all integrins in prostate tumour development. Overall reviews are available which profile 
integrin expression in prostate cancer (Alghisi and Ruegg, 2006; Goel et al., 2009; Goel et al., 
2008; Lu et al., 2008).  
The advent of new high-throughput genotyping technologies has permitted rapid and 
significant advances in our understanding of the genes contributing to prostate cancer. In 
particular, genome wide association studies (GWAS) have permitted the identification of 
common genetic susceptibility variants associated with a significantly increased risk of 
developing the disease. These discoveries are now providing insight into the biological 
pathways that determine how disease arises, tumour progression, and the acquired 
propensity to metastasise. Whilst the role of the vast majority of these variants in prostate 
cancer remains to be determined, these studies have identified biological pathways 
important in the development of disease. The integrin family of cell adhesion molecules has 
recently featured both in the search for prostate cancer susceptibility genes, and in 
comparative analyses of genetic susceptibility variants and gene expression profiling studies 
of prostate tumours. Further, studies using a variety of approaches to identify the key 
drivers of prostate tumour development and progression have identified selected integrins 
as key molecules in these processes. Indeed, these studies have highlighted integrins as 
potential therapeutic options against prostate cancer. Here we provide a new perspective on 
the role of the integrins α2, α6 and β4 in prostate cancer risk and progression. Whilst these 
receptor subunits have not previously featured prominently in prostate tumour biology, 
their role in prostate tumour development has more recently come to the fore through the 
application of next generation molecular techniques to gene discovery in prostate cancer 
and prostate tumour stem cell studies.  
2. Integrin genetic variants and prostate cancer 
Family history remains the most frequently identified risk factor for developing prostate 
cancer, in addition to advancing age. A family history of disease is indicative of an 
underlying inherited genetic predisposition. Indeed, population studies have repeatedly 
identified increased risk to relatives of those diagnosed with this cancer. Despite intensive 
research over more than a decade, the genetic contributors to prostate cancer remained 
poorly understood. It was not until large scale genome-wide association studies became 
possible utilising high-throughput genotyping with commercially available arrays that 
rapid advances in our knowledge of the genetic contributors to prostate cancer and indeed 
other complex diseases became possible. These advances permitted the genotyping of 
hundreds of thousands of single nucleotide polymorphisms (SNPs) to test for association 
with a disease in large numbers of cases and controls. Using this approach, over 30 prostate 
cancer susceptibility variants have now been identified. These studies have identified 
genetic variants both in known genes and intergenic regions associated with risk of disease. 
However, it has become clear that for only for a select few is the role of the variant identified 
determining prostate cancer risk apparent. For example, the significantly associated variant, 
rs10993994, in the MSMB1 gene (Eeles et al., 2008) is located within 2bp of transcription 
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initiation site, and has been demonstrated to influence transcriptional activity (Chang et al., 
2009). However, to date the functionality of the vast majority of the SNPs identified, many of 
which are not within or close to known genes, remains unknown. Thus, there are still 
significant gaps in our understanding of genetic contributors to prostate cancer susceptibility 
which is impeding translation of these exciting advances into the clinical setting. 
Variants within the ITGA6 gene, which codes for the α6 integrins, has recently been 
identified as contributing to the genetic risk of prostate cancer. A large, multi-stage 
international collaborative GWAS utilising over 30,000 cases and controls has identified 
seven novel prostate cancer susceptibility loci. One variant identified as significantly 
associated with disease risk is in intron one of the ITGA6 gene (Eeles et al., 2009). The SNP 
identified was rs12621278 on chromosome 2q31 (per allele odds ratio=0.75, confidence 
interval=95% P=8.7x10-23) (Eeles et al., 2009). Most interestingly, Cheng et al., (2010) have 
since screened 26 SNPs identified by previous GWAS studies (Duggan et al., 2007; Eeles et 
al., 2009; Eeles et al., 2008; Gudmundsson et al., 2009; Gudmundsson et al., 2007; 
Gudmundsson et al., 2008; Thomas et al., 2008) in 788 patients that had undergone radical 
prostatectomies to test for association with aggressive cancer. Five of these SNPs were 
independently associated with prostate cancer progression; however, the most strongly 
associated risk variant identified was in ITGA6 (rs12621278), where a 2.4 fold increase risk of 
prostate cancer progression (P=0.0003) was reported to be associated with the risk allele. 
This integrin is also known to play an important role in prostate cancer stem cell biology, 
vascularisation and metastasis. Thus, given the known role of this integrin in prostate 
tumour development, this may represent an opportunity for targeted therapy in those cases 
with ITGA6 associated genetic susceptibility. 
By employing a genome wide linkage approach in the study of familial prostate cancer, 
we have identified a second integrin as significantly associated with prostate cancer risk 
(FitzGerald et al., 2009). A region on chromosome 5p13q12 was highlighted by genetic 
linkage analysis of a large family with multiple, densely aggregated cases of prostate 
cancer. Two polymorphisms were subsequently found to be significantly associated with 
prostate cancer risk. The SNP rs3212649 was identified within the three prime 
untranslated region (3’-UTR), and a second polymorphism, rs1126643 (C807T), located in 
exon seven. Variant rs3212649 was the most strongly associated with disease in the 
familial cases (OR=2.43 CI=1.28-4.58) but also in the combined dataset comprising both 
sporadic and familial cases (OR=1.67 CI=1.07-2.60). This SNP had not been previously 
reported to be associated with cancer risk. The C807T SNP was also significantly 
associated with increased prostate cancer risk both in the familial (OR=2.16 CI=1.19-3.92) 
and combined datasets (OR=1.52 CI=1.01-2.28). Furthermore, the C807T variant has also 
been previously associated with an increased risk of oral cancers, and also advanced 
breast cancer (Langsenlehner et al., 2006; Vairaktaris et al., 2006). Whilst presence of the 
alternate allele at C807T does not alter amino acid sequence, it has been reported to be 
associated with altered levels of expression of the α2 receptor on the cell surface 
(Jacquelin, 2001). It should be noted that there exists significant linkage disequilibrium 
between rs3212649 and rs1126643 and a number of other SNPs located in the 3’-UTR of 
the ITGA2 gene. ITGA2 is also known to play an important role in prostate cancer stem 
cells, angiogenesis and tumour spread and also represents an exciting opportunity for 
target therapy. The mechanism by which these susceptibility variants influence ITGA2 
gene expression is currently under investigation in our laboratory. 
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Whilst these GWAS are identifying genetic variants significantly associated with disease 
risk and progression, the functional implications of many of these variants and their 
relevance to disease remains to be determined (Manolio, 2010). Thus, the results of GWAS 
have been examined in combination with microarray gene expression data, providing a 
systematic approach to the examination of genetic variants associated with disease and 
observed changes in gene expression. Gorlov et al. (2009) performed a meta-analysis on 
gene expression data from normal prostate tissue and prostate tumour tissue, and combined 
it with a GWAS meta-analysis to identify sets of genes over-represented in both types of 
studies. Cell adhesion genes including α2, α6 and β4 integrins feature prominently amongst 
the most significantly associated genes and also the most differentially expressed reported 
in the microarray study (Gorlov et al., 2009). Gorlov and colleagues (2009) also highlight 
cadherins and integrins as important modulators of prostate cancer development and 
further argue that whilst GWAS-identified genes are considered to be cancer susceptibility 
genes associated with tumour initiation, the detection of a tumour requires a minimum 
tumour size and thus those identified from GWAS are also likely be detecting variants 
association with tumour progression. 
3. Integrin α2 and α6 in stem cells 
The concept that most solid tumours, including prostate cancer, arise from cancer stem 
cells possessing the capacity for self-renewal and tumour initiating capacity has led to the 
search for tumour cell populations with “stem-cell like” properties. Collins et al. (2001) 
were the first to demonstrate a primary human prostate tumour cell subpopulation with 
the capacity for self renewal and high clonogenic potential. These cell populations were 
characterised by high expression of CD44, α2β1, and CD133. Subsequent studies have also 
identified prostate cancer stem cell populations (Collins, 2005; Guzman-Ramirez et al., 
2009; Li, 2008). Guzman-Ramirez et al., (2009) recently isolated cells from surgically 
excised human prostate tumour tissue and culture of these tumour derived cell 
populations termed “prostaspheres” resulted in sub-populations expressing high levels of 
both the α2 and α6 integrins. Furthermore, Eaton et al. (2010) have examined the tumour 
cell stem cell phenotype in 11 matched primary and bone metastasis specimens from 
prostate cancer patients for the presence of a number of putative stem cell markers. No 
definitive pattern was observed which established a single marker profile of the 
metastatic phenotype; integrins α2 and α6 were relatively widely expressed across the 
metastases series in nine of eleven tumours examined. Other groups have since 
characterised prostate cancer stem cell populations expressing stem cell markers 
including OCT3/4, BMI1, β-catenin and SMOOTHENED in addition to α2 and α6 integrins. 
Most recently, several studies have identified a link between prostate cancer stem cells 
and epithelial to mesenchymal transition (EMT) demonstrating the link between the 
biology of prostate cancer stem cells, EMT and the propensity to metastasise (Kong et al., 
2010; Mathews et al., 2010). EMT occurs during normal embryonic development; however, 
more recently, it has been identified as one of the early stages in the transition from 
confined tumours to invasive malignancies. The loss of epithelial cell phenotype and the 
gain of mesenchymal phenotype is accompanied by increased cell motility and 
invasiveness. This is accompanied by the loss of markers of epithelial phenotype and gain 
of mesenchymal markers. Profiling of expression of α2 and α6 integrin expression and EMT 
in prostate tumours has only recently been examined (Neal et al., 2011). SNAIL, a key 
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factor promoting EMT decreases cell adhesion and increases α2 and β1 expression (Neal et 
al., 2011). However, there is evidence that known regulators of EMT, for example ZEB1 
influence expression of ITGB4 (Drake et al., 2010), and down-regulation of α6β4 in the 
prostate cancer cell line SNAI2 knockdown studies in PC3 cells (Emadi Baygi et al., 2010) 
However, EMT in prostate cancer remains controversial.  
4. Expression profiles of α2 and α6 integrins 
Investigations of integrin expression patterns in prostate tumours stratified by tumour 
stage have produced inconsistent findings. Studies of α2β1 expression in tumours report 
that expression patterns are abnormal in both primary tumours and lymph node 
metastases (Pontes-Junior et al., 2009). Whilst there have been several apparently 
conflicting reports, it appears that normal prostate basal epithelium expresses high levels 
of α2 which is down regulated in primary tumours, with conflicting results in metastases. 
For example, studies of primary and metastatic prostate carcinomas have reported that 
α2β1 expression is down-regulated in low grade tumours, heterozygous in intermediate 
grades, and up-regulated in lymph node metastases (Bonkhoff et al., 1993; Knox et al., 
1994; Kostenuik et al. 1996). Mirtti et al., (2006) have reported differential expression 
levels in prostate tumour cell lines, and lower α2 mRNA and protein expression in higher 
grade tumours when compared to benign lesions, although the levels of mRNA 
expression reported by Mirtti et al. (2006) again varied widely in tumours. Moreover, α6 
expression has been shown to be up-regulated in metastases and adenocarcinoma 
(Bonkhoff et al., 1993; Knox et al., 1994; Nagle et al., 1995; Schmelz et al., 2002), whereas α2 
has been shown to be down-regulated in adenocarcinomas and up-regulated in metastatic 
tumours (Bonkhoff et al., 1993; Nagle et al., 1995). This variable level of expression 
observed in prostate tumours is also evident in expression array analyses of α2β1 in 
prostate tumours, published in the NCBI GEO database (Edgar R, 2002). Ramirez and 
colleagues (2011) combined previously published microarray studies (Lapointe et al., 
2004; Tomlins et al., 2007) to identify that α2β1 expression was markedly reduced or lost 
with tumour progression in prostate and breast cancer. In normal prostate tissue, α2 is 
highly expressed and Ramirez et al., (2011) have shown that α2 expression decreases 
progressively as prostate cancer proceeds from PIN lesions, to prostate cancer and then to 
metastatic prostate cancer where α2β1 expression is completely absent. Ramirez et al. 
(2011) also suggests that α2β1 may be a prognostic biomarker for identifying patients at 
risk of metastasis. 
Using the profile of overall integrin expression as a predictive tool to measure patient 
outcomes has received some investigatory attention. Pontes-Junior et al. (2010) measured 
expression levels of eight integrins (α2β1, αvβ3, αIIbβ3, αv, α3β1, α3, β4 and α6) in resected tumour 
tissue from patients with localised prostate cancer, and found that the expression level of 
integrins α3 and α3β1 were associated with poor outcomes after a follow up period of ten 
years (2.5 and 3 fold higher respectively). The majority of integrins were down-regulated in 
tumour tissue with the exception of α6, consistent with previous studies (Cress et al., 1995; 
Edlund et al., 2001; Rabinovitz et al., 1995; Schmelz et al., 2002) where its ability to bind 
ligands such as laminins and collagens is associated with increased invasiveness and 
metastases to bone. Down-regulation of α2β1 in the early stages of prostate and breast 
tumour development has been reported to be associated with poor outcomes, with up-
regulation of this integrin in metastasis. Interestingly, increased expression has been 
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reported in colorectal cancer (CRC) and ovarian cancer to be associated with tumour cell 
spread (Luque-Garcia et al., 2010). 
It should perhaps be noted that studies examining integrin expression profiles at different 
stages of tumour development vary in the integrin subunits targeted for 
immunohistochemical analysis, some targeting single subunits, others heterodimeric 
complexes. Edlund et al. (2001) observed a change from normal prostate tissue expressing 
α6β1 and α6β4 to tumour tissue expressing only α6β1. This loss of the β4 subunit in 
carcinomas of the prostate was attributed to differential binding caused by the two 
different isoforms of α6 (α6A and α6B). Integrin α6A which is expressed by the prostate 
cancer cell line LNCaP, preferentially binds to β1, which is known to have high metastatic 
ability (Edlund et al., 2001). Therefore, examining changes in heterodimer ratios combined 
with isoform data may provide a more detailed profile of the α2 and α6 contribution to the 
prostate cancer biomarker model. The variable expression of these integrins in prostate 
tumour samples is perhaps reflective of the recognised heterogeneous nature of prostate 
tumours. Further, this observation is supported by the ability to derive sub-population 
cells expression high levels of α2 and α6 and with “stem cell-like” properties from prostate 
tumours expression. It is also worthwhile noting that examining the integrin expression 
profiles in tumours may not take into account individual genotype-driven variation in 
gene expression. 
5. Animal models of prostate tumour metastasis and angiogenesis 
Animal models have proven useful in the examination of the role of integrins in driving 
prostate tumour metastasis. In a study aiming to identify the critical molecules regulating 
prostate tumour metastasis, Hall et al. (2006) utilised LNCaP cells, a cell line of low 
tumourigenic potential that does not form metastases in mouse models. Selection by 
growth of LNCaP cells on type I collagen resulted in the generation of the derived 
LNCaPcol subline with enhanced chemotactic capacity. This subline expressed high levels 
of α2β1 receptor (in contrast to the parent line) and chemotactic capacity was inhibited by 
α2β1-specific antibodies. Further, upon injection of the derived LNCaPcol cell line into the 
tibia of nude mice, 53% of mice developed bony lesions compared with 0% of those 
injected with parental LNCaP cells. In similar studies, van Slambrouck et al. (2009) have 
demonstrated that the high bone metastatic potential of the subline, C4-2B, derived from 
LNCaP cells, is mediated by α2 signalling. This signalling results in down-stream 
activation of the critical FAK/src/paxillin/Rac/JNK pathway and activation of 
metalloproteinases, MMP2 and MMP9, known to play a central role in tumour invasion. 
Furthermore, van Slambrouck et al. (2009) argue that it is redistribution and clustering of 
α2 on the cell surface in their model that activates downstream signalling, rather than 
altered receptor level as observed by Hall et al. (2006). King et al. (2008) have also utilised 
a derivative of the prostate cancer cell line PC3 in a mouse xenograft model to 
demonstrate a role for α6 in the growth of prostate tumours in bone. PC3N cells were 
transfected with wild-type and functional mutant α6 subunits and stable transfectants 
were injected into femurs of severe combined immuno-deficient (SCID) mice. Whilst both 
wild-type and mutant transfected PC3N cells established bone tumours, the study showed 
the PC3N-α6 mutant transfected cells showed dramatically reduced invasion of bone 
marrow and less tumour associated bone loss. 
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The α2β1 receptor also plays a key role in developmental angiogenesis signalling via the 
VEGF pathway. In a Lewis lung carcinoma (LLC) xenografts model, α2β1 null mice exhibited 
no response to angiostatic agents targeting α2β1 in contrast to wild-type mice (Woodall et al., 
2008). Interestingly, it appears that this effect may be tumour cell dependent, a phenomenon 
also reported by Zhang et al. (2008), with current evidence suggesting that tumour cell 
characteristics, such as α2β1 integrin expression, and the interactions with the surrounding 
tissue environment, under the influence of host genetic factors, determine tumour 
development and/or metastasis. This is in keeping with the “soil determining the seed” 
hypothesis of tumour metastasis. 
6. Epigenetic regulation of integrins α2 and α6 
Events causing up-regulation or down-regulation of genes, whether they are DNA based 
sequence changes or epigenetic events can function to disrupt key genes in cancer 
development. It is now clear that epigenetic alterations feature prominently in abnormal 
growth states and there is strong evidence that these alterations can predict tumour 
behaviour. The apparent paucity of functional loci identified by GWAS and gene expression 
studies in prostate cancer has also led many research groups to focus on the epigenetic 
mechanisms influencing gene expression. Evidence that some epigenetic regulatory 
mechanisms are uniquely sensitive to environmental factors, such as diet and oxidative 
stress, may be an important mechanism by which environmental factors influence cancer 
risk (Dobosy et al., 2007). These mechanisms include DNA methylation, histone 
modification and micro RNAs (miRNA). 
Segments of DNA rich in CpG motifs, also known as CpG islands, are the targets for DNA 
methylation. CpG islands, when present in gene promoters, are an important mechanism by 
which genes can be regulated by the addition or removal of methyl groups at key CpG 
motifs. This permits differential expression of genes in different cell types. DNA 
methylation occurs at cytosine-guanine repeats where a methyl group is attached to a 
cytosine residue by a DNA methyltransferase or DNMT. DNA methylation can affect gene 
transcription in two ways: either by preventing the transcriptional machinery from binding 
or by becoming targets for chromatin remodelling proteins. Global de-methylation or hypo-
methylation has been reported in the promoter region of genes causing dysregulation and 
thus overexpression of genes including oncogenes (Ehrlich, 2009). Dysregulation of the 
genes that control for normal cellular function, such as integrins, can cause an over 
proliferation and thus tumour growth.  
In disease states such as cancer, disrupted methylation can permit aberrant silencing or re-
expression of key genes contributing to tumour development. Epigenetic alterations are a 
feature of both benign prostatic hyperplasia and prostate tumour development. There is a 
significant body of evidence highlighting the role of DNA methylation in prostate cancer. 
However, it is evident from these studies that these changes are complex, with both global loss 
of methylation across the genome occurring in addition to localised hyper-methylation of gene 
promoters. Global hypo-methylation is associated with chromosomal instability and activation 
of proto-oncogenes whilst gene-specific hyper-methylation frequently results in silencing of 
tumour suppressor genes. In particular, the research has focussed on the identification of a 
panel of genes that are hyper-methylated in prostate cancer with several key genes identified 
for example GSTP1 (Dobosy et al., 2007). As discussed later in this chapter, therapies 
attempting to reverse silencing of tumour suppressor genes in cancer are of current interest. 
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However there is also some evidence suggesting that agents promoting de-methylation may 
actually enhance tumour development, by increasing the expression of genes promoting 
tumour development (Shukeir et al., 2006). 
6.1 DNA methylation and chromatin remodelling 
Whilst there has been significant advances in our knowledge of a range those genes altered 
by epigenetic changes in prostate cancer, at present studies examining epigenetic alteration 
of integrin gene expression and its role in prostate cancer are limited (Chen et al., 2009; Park 
et al., 2004; Uhm et al., 2010; Yang et al., 2009). In experiments utilising bisulphite 
sequencing of cloned DNA derived from prostate cancer cell lines conducted in our 
laboratory, we have observed that altered methylation of the ITGA2 promoter is associated 
with altered gene expression (data not shown). At present, there is no evidence that the α6 
gene promoter is regulated by altered methylation. However, Yang et al. (2009) have 
reported the β4 integrin is regulated by both methylation changes and histone modifications. 
Further, the loss of β4 expression in mammary gland cells is associated with increased 
methylation of the β4 promoter and an increase in repressive histone modifications and EMT 
(Yang et al., 2009). In addition, enzyme specific assays and bisulphite sequencing reveal that 
the LNCaP cell lines displayed higher methylation levels than PC3s and this is correlated 
with gene expression. Our results strongly suggest that ITGA2 expression may in fact be 
regulated by epigenetic mechanisms (data not shown). 
While yet to be reported in prostate cancer, another mechanism by which integrin 
epigenetics can regulate gene expression is by chromatin remodelling. Chen et al. (2009) 
report that integrin α6β4 indirectly affects gene transcription by chromatin remodelling. 
Several genes including FST, S100A4, NKx2.2, PDLIM4 and CAPG in which expression was 
previously shown to be controlled by DNA methylation were significantly up-regulated by 
the expression of α6β4. In addition the inhibition of DNMTs in cells lacking the α6β4 cell line 
stimulated the expression of these genes. These results suggest that α6β4 can alter the 
expression of particular genes by stimulating de-methylation at their promoters. Further 
studies are required to characterise the role of epigenetic mechanisms in the regulation of 
gene expression of integrins in prostate cancer.  
6.2 Micro RNAs 
Perhaps the most recent and exciting area of epigenetic regulation in prostate cancer is the 
field of micro RNAs (miRNA). MiRNAs are small molecules typically 17-22bp in length 
which binds to the 3’-UTR and either degrade the mRNA directly or prevent it from being 
translated. This post transcriptional regulation is particularly dependent on the ‘seed region’ 
of the miRNA which constitutes the first 7bp-9bp of the miRNA. A number of software 
programs are available (DIANA, mictoT and PITA), which vary in their predictions 
depending on the parameters and algorithms used in their design. Polymorphisms within 
the seed region can alter whether a miRNA will bind or change the energy with which it 
will bind to the mRNA. These allele specific changes indicate that miRNAs can act as either 
oncomiRNAs or tumour suppressors, and array studies can contribute to increasing the 
precision with which tumours are characterised (Zhang et al., 2007). MiRNAs are normally 
associated with decreased levels of gene expression, as one of the established mechanisms of 
action is to suppress translation and promote degradation of their target mRNAs. However, 
up-regulation of genes following transfection of miRNAs predicted to bind to sequences in 
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their 3’-UTRs has been previously reported in a number of studies reviewed by Khan et al. 
(2009). The potential role of miRNAs in the regulation of integrins in breast cancer was 
examined by Brendle et al. (2008). In a novel approach, miRNA binding site predictive 
software was used to predict altered miRNA binding to the 3’-UTRs of several integrins at 
the location of known genetic variants within these regions. A miRNA binding site was 
predicted to be altered by the alternate allele at rs743354. Upon subsequent examination it 
was observed that this SNP within the 3’-UTR of ITGB4 was significantly associated with 
oestrogen receptor status and survival in breast cancer patients. In an approach similar to 
that taken by Brendle et al. (2008), we have determined that several of the SNPs associated 
with prostate cancer risk in the 3’-UTR of the ITGA2 gene are located in miRNA binding 
sites. The presence of the alternate allele alters the binding affinity of the miRNA. Our 
current work is investigating the role of the specific miRNAs in ITGA2 gene regulation.  
7. Integrin α6 and α2 in prostate cancer therapeutics 
Integrins represent ideal therapeutic targets as they are cell surface receptors that interact 
with extracellular ligands (Lu et al., 2008). The notion of integrins as therapeutic targets has 
been explored over a number of years, and there are two main mechanisms by which they 
have been targeted. Integrins are potentially important diagnostic biomarkers for cancer 
detection and progression, as it has been particularly relevant for prostate cancer which is 
historically difficult to diagnose with the inherent variability associated with the prostate-
specific antigen (PSA) test and associated risks that accompany the collection of biopsy 
tissue. Secondly, they continue to be targeted directly as a method of preventing 
oncogenesis. In particular, they have been targeted as therapeutic options for metastases, as 
they are key mediators of cell dissemination and tumour growth via the angiogenesis 
pathways. Several of these integrin based therapies have shown promise in late stage 
cancers, extending life expectancies by several months in some cases. Further, it is often in 
conjunction with other adjuvant therapies such as chemotherapy and radiotherapy that 
integrins show the most promise as therapeutic agents. As we move forward into an era of 
personalised medicines it seems likely that integrins will have a major role to play. 
7.1 Antibody based therapies 
Integrin-targeted therapies have been of interest for a number of years, however few have 
targeted α6 and α2 heterodimers, and even fewer have been examined in relation to prostate 
cancer. The majority of studies have focussed on preventing angiogenesis and thus tumour 
growth, with most examining the αv heterodimers. However, recently, studies have begun 
to shift towards the role of α2 and α6 in cancer models (Table 1). One of the more promising 
studies that has undergone human trial utilised α2 as a platelet biomarker for an anti-
integrin drug E7820, a derivative of an aromatic sulphonamide compound (Funahashi et al., 
2002). E7820 inhibits angiogenesis via the VEGF or basic fibroblast growth factor (bFGF) 
pathways, and has been shown to inhibit the α2 mRNA transcription in human umbilical 
vein endothelial cell (HUVEC) cultures and, importantly for prostate cancer, it has also been 
shown to inhibit vascular formation in a type I collagen matrix (Semba et al., 2004). E7820 
administered orally twice daily by mice with sub-cutaneous KP-1 tumours displayed a 
decreasing expression level of α2 on platelets which was positively correlated with anti-
tumour activity (Semba et al., 2004). Stage I trials of E7820 have been completed and stage II 
trials have commenced, examining the efficacy of E7820 in conjunction with Cetuximab (a 
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monoclonal antibody, targeting the epidermal growth factor receptor EGFR) in metastatic 
colorectal cancer (mCRC)(ClinicalTrials.gov, 2011b). To date, E7820 combined with 
Cetuximab, has been well tolerated in patients with advanced metastatic CRC. Integrin α2 
expression levels decreased by 82.1% without significant disruption of platelet function, 
with median progression-free survival increasing by 1.9 months and median overall 
survival increasing by 9.6 months (Sawyer, 2010). In addition, stage II trials of E7820 
administered in conjunction with FOLFIRI (FOL-folinic acid, F-5-flourouracil and IRI-
irinotecan), a traditional chemotherapeutic agent have also commenced in patients with 
mCRC. This study has begun with the premise of testing the tolerability and efficacy on 
mCRC for those who have failed first round treatment, before moving on to a larger cohort 
of patients (ClinicalTrials.gov, 2011a). 
Integrins α1β1 and α2β1 play a significant role in driving angiogenesis (Lu et al., 2008) and 
antibodies targeting the α2 receptor have shown promising results in vivo. Anti α2 antibody 
Ha1/29 inhibited endothelial cells in an immobilised collagen gradient assay by 
approximately 40% (Senger et al., 2002). In addition, Senger et al. (1997; 2002) also applied a 
combination of anti-α1β1 and α2β1 antibodies to mice harbouring the human A431 squamous 
cell xenografts which resulted in decreased tumour growth <60% and angiogenesis <40%. 
The inhibitory effect of anti-α2 antibodies on endothelial cells in a collagen matrix is likely to 
be particularly pertinent to prostate cancer where 80% of metastases are to bone; where 
collagen, the most abundant ligand of α2, is abundant. Alghisi and Ruegg (2006) suggest that 
a humanised form of Ha1/29 may be a useful anti-angiogenesis target, and this may be 
particularly relevant for prostate cancer. Furthermore, antibodies against α2 have been 
shown to reduce the invasive capability of mouse mammary carcinoma cells across the 
basement membrane (Lochter et al., 1999). This was found to be regulated by the expression 
of the matrix metalloproteinase stromelysin-1. The relationship between MMPs and 
integrins has been well documented and may represent another avenue for targeted cancer 
therapy. Murine based anti-α6 antibodies have also been utilised by Ruiz et al. (1993) who 
illustrated a lower ability for human melanoma cells to metastasise in nude mice. Metastases 
were inhibited when the antibody EA-1 was injected in to the mice either before or 
simultaneously with the melanoma cells (Ruiz et al., 1993). 
7.2 RGD peptide / disintegrin based therapies 
Integrin α2β1 has been implicated in mediating the effects of peptides designed to target the 
matrix bound tumour associated protein, angiocidin. Angiocidin is a protein that is found in 
the sera of patients with melanoma, colon, prostate and breast cancer, in levels that correlate 
with the progression of the disease, indicating that angiocidin may regulate tumour 
progression (Gaurnier-Hausser et al., 2008). Disintegrins or RGD based peptides are small, 
soluble molecules that originate from viper venom toxin and target the RGD (arginine-
glycine-aspartate) motif. A 20 amino acid N–terminal peptide disintegrin of angiocidin has 
been shown to bind to integrin α2β1 in K562 cells (a myelogenous leukaemia cell line) and 
ligate type I collagen on epithelial and tumour cells in a mouse model (Sabherwal et al., 
2006). Soluble peptides that bind to α2β1 integrins at the RGD motif are therefore able to 
prevent cell attachment and thus induce apoptosis (Buckley et al., 1999). In vitro angiocidin-
inhibitory peptide trials have been demonstrated to be well tolerated and to reduce cancer 
burden in murine colon cancer models, with reductions in primary tumour volume and 
tumour burden (Liebig et al., 2007). 
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Table 1. A summary of agonists targeting the α2, α6 and β4 integrins. Treatments that have 
reached phase II of human trial are denoted *. Efforts to reduce tumour progression by 
targeting angiogenesis with small peptide based molecules have proven promising. The 
protein fragment endorepellin which is derived from the C-terminus of perlecan a basement 
membrane and scaffold protein displays remarkable anti-angiogenic properties (Bix et al., 
2007). Bix et al. (2007) have reported a significant decrease in vasculature in an LLC mouse 
model (P=<.001) and interestingly observed that the administration of endorepellin 
immediately prior to the appearance of the tumours almost completely blocked their growth. 
Furthermore, Woodall et al. (2008) identified that the anti-angiogenic effects of endorepellin 
did not occur in the absence of α2β1. The experiment showed that α2β1 knockout mice displayed 
significantly less vasculature than wild-type mice (P=<.0001). Integrin α2β1 was necessary for 
the recruitment of endorepellin to the vasculature where it conjugated with the α2 domain in a 
cation-independent manner and supressed angiogenesis (Woodall et al., 2008).  
Drug Type Target Tumour/ cell type Reference 
E7820 Peptide α2 
Broad spectrum anti-
tumour activity in seven 
cell lines and murine 
models 
(Funahashi et al., 2002), 




















cell line, murine colon 
cancer models 
(Sabherwal et al., 2006), 




α6β1 DU145 prostate carcinoma cell line 
(DeRoock et al., 2001), 





Lewis lung carcinoma 
model, HT1080 and A431 
cell lines 
(Bix et al., 2007), (Woodall 




α2β1 C4-2B and HT1080 cell lines 
(Savore et al., 2005), 























PC3 and LNCaP prostate 
carcinoma cell lines 
(Wedel et al., 2011) 
Pabinostat & 
rapamycin 
HDAC and mTOR 
inhibitors 
α2, β1 PC3 and C2 prostate and renal carcinoma cell lines (Verheul et al., 2008) 
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Preceding, and contrary, to these findings is that perlecan the precursor molecule from 
which endorepellin is derived was also found to have anti-angiogenic and tumour 
suppressing qualities in prostate cancer (Savore et al., 2005). The suppression of perlecan 
expression with siRNA in the androgen independent bone targeted cell line C4-2B caused 
a reduction in colony size and the cohesiveness of transfected sub-clones in anchorage–
independent growth assays. Further, when injected into athymic mice they showed a 
reduced growth rate, tumour size, vasculature and a failure to elevate PSA levels (Savore 
et al. 2005). Similar results have also been reported by Mathiak et al., (1997) in the HT-
1080 fibrosarcoma cell line where perlecan cDNA transfected in antisense orientation 
caused an increased invasiveness through matri-gel coated filters, increased migratory 
ability through 8µm filters and elevated adhesiveness to type IV collagen substrate. These 
results are seemingly incongruent with the more recent findings of Bix et al. (2007) and 
Woodall et al. (2008) that a reduction of perlecan should in theory reduce the endogenous 
levels of the derivative endorepellin and thus increase tumour growth. Woodall et al., (2008) 
suggests that is quandary can be reconciled by “the unique dependence” of HT-1080 cell line 
on integrin α2β1. 
While RGD based peptides represent a good target for the collagen binding integrins such as 
α2, unfortunately the laminin binding integrins such as α6 and β4, which bind in a RGD 
independent manner, are not clinically useful agonists for RGD mimicking peptides 
(Cheresh and Spiro, 1987). Therefore, additional therapeutic development is required to 
target this group of integrins. A D-amino acid peptide KIKMVISWKG (HYD-1) has been 
shown to bind to integrin α6β1 in the human prostate carcinoma cell line DU-145 (DeRoock 
et al., 2001). The HYD-1 peptide was illustrated to prevent cellular attachment to ECM 
proteins and dermal cell fibroblasts (DeRoock et al., 2001). The finding that α2 and α6 can be 
bound by peptides is important and preliminary evidence suggests that they are well 
tolerated in murine models, intriguingly, DeRoock et al. (2001) also suggests that peptide 
administration can ‘sensitise’ cancer cells to radiotherapy, and aid the removal of cancer 
cells refractory to primary treatment. 
7.3 siRNA based therapies 
Antisense and siRNA oligonucleotides have enormous potential as therapeutic agents in 
prostate cancer and cancers in general (Juliano et al., 2011). Currently, siRNA 
oligonucleotides which target the α6β4 subunit have been shown to reduce migratory and 
decrease the invasive capability of the breast carcinoma cell line MDA-MB-231 (Lipscomb et 
al., 2003). It is now clear that targeting one integrin with siRNAs can also lead to increased 
expression in another integrin. For example Defilles et al. (2009), knocked out αvβ5 and αvβ6 
using several antibodies and disintegrins, which caused the expression of α2β1 to increase. 
This negative crosstalk between αvβ5 and αvβ6 integrin also unexpectedly interfered with 
P13Kinase regulated α2β1 mediated migration (Defilles et al., 2009). This dynamic crosstalk 
between integrins needs to be considered when administering integrin-targeted therapies. 
It may be that a suite of different disintegrins will need to be developed to target the 
numerous different integrins expressed on the cellular surface to effectively combat cell 
migration and oncogenesis. While the results using siRNAs in vitro are extremely 
promising, difficulties have arisen attempting to deliver these molecules to targeted 
regions in the animal model. Delivering oligonucleotides into cells in the absence of 
transfecting reagents is extremely difficult, given their potential as therapeutic agents a 
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suite of mechanisms have been attempted including lipoplexes, polymers and dendrimers 
(reviewed by Juliano et al., 2011).  
Integrins are recycled by endocytotic mechanisms and thus represent a particularly 
attractive mechanism in which siRNAs and small oligonucleotide delivery and efficacy can 
be improved. To date, delivery improvement has been made by utilising RGD peptides 
conjugated to oligonucleotides in the presence of polyethylene glycol (PEG). PEG acts as a 
protective mechanism against phagocytosis and also allows the peptides to remain 
functional for a longer period by reducing the interaction with negatively charged cell 
surface proteoglycans (Juliano et al., 2011). Additional PEG-RGD mediated cellular entry 
mechanisms have incorporated oligonucleotides into cationic lipoplexes and utilised nano-
carrier technology, where upon cellular entry siRNAs are released and transported via 
cellular pathways (Juliano et al., 2011).  
7.4 Epigenetic therapies 
Genes altered by epigenetic modification in cancer are of current interest both as diagnostic 
markers and as targets for epigenetic modifiers as therapeutic agents. Histone modification 
or altered DNA methylation of α2 and α6 integrins as potential targets for such therapies in 
prostate cancer have not been widely investigated; however, there is preliminary evidence 
that their activity is targeted by such therapeutic targets. Recently, Wedel and colleagues 
(2011) have demonstrated in vitro that two drugs, Valproic acid (VPA) and RAD001 reduce 
tumour cell invasion, migration and adhesion of the prostate cancer cell lines PC3 and 
LNCaP. Valproic acid is a histone deacetlyase inhibitor and RAD001 is a mammalian target 
of rapamycin (mTOR) inhibitor. Previous studies have shown that mTOR and Akt 
phosphorylation is highly correlated with Gleason grade and mTOR has been shown to be a 
significant prostate cancer biomarker (Dai et al., 2009; Kremer et al., 2006) The separate 
application of RAD001 or VPA significantly reduced cell adhesion, migration and invasion 
in PC3 and LNCaP cells, and combination therapy proved to have an additive effect both on 
migration and invasion but curiously not adhesion. Furthermore, the addition of VPA and 
RAD001 also changed the cell surface expression of integrins in both cell lines, 
significantly altering the expression of α2, α6 and β4 integrins. More specifically, the 
addition of VPA caused a significant down-regulation of α6 and β4 integrins in PC3 cells 
and in LNCaP cells α2 and α6 were significantly up-regulated. Given the differential 
response to the application of VPA to the androgen independent PC3 and androgen 
dependent LNCaP cell lines, the authors speculate that early and late stage tumours may 
vary in their response to the application of VPA (Wedel et al., 2011). The simultaneous use 
of pabinostat (LBH589), also a HDAC inhibitor with rapamycin, also had an additive 
effect in another prostate cancer model, in particular on the α2 and β1 integrins, key 
drivers of the metastasis (Verheul et al., 2008). 
8. Conclusion 
Approximately one in seven men are now diagnosed with prostate cancer over their 
lifetimes; clinicians still lack the ability to identify those tumours that are likely to be 
aggressive with a propensity to metastasise. There have been significant advances in our 
understanding of the genetics of prostate cancer, with genetic analyses and gene expression 
studies highlighting the integrins as key molecules driving prostate cancer and 
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susceptibility and progression. While many early studies have examined the αv integrins, 
here we have highlighted the importance of α2, α6 and β4 in prostate cancer. The 
characterisation of prostate cancer stem cells has identified α2 and α6 integrins as important 
markers in stem cells and may suggest an emerging role for these integrins in EMT, a key 
event in tumour progression. Further, the integrins α2 and α6, which bind to collagen and 
laminin, have been identified as key drivers of prostate cancer metastasis, particularly to 
bone. Given that the vast majority of prostate cancer deaths are associated with metastatic 
disease, with over 80% of these metastases occurring in bone, this represents an exciting 
avenue for therapeutic development. Advances in technology, such as next generation 
sequencing, have provided new tools for mapping genetic and epigenetic changes 
associated with tumour development. Over 30 prostate cancer susceptibility loci have been 
identified to date, contributing approximately 25% relative risk; however, critical questions 
remain as to how these genetic changes identified influence gene function and thus prostate 
cancer. Therefore, there remains a need to address these current gaps in our understanding 
of genetic susceptibility and how these variants actually influence disease risk and 
progression, as we are still waiting for the translation of the vast majority of these findings 
into the clinical setting. Studies of cancer genes have generally focused on elucidation of 
mutations, deletions or amplification of critical growth promoting or suppressor genes. It is 
now clear that small molecules that control post transcriptional gene expression such as 
miRNAs, or aberrant DNA methylation, and chromatin remodelling are also known to 
contribute to prostate cancer development and progression and are proving attractive 
targets for future cancer therapies. Knowledge of how therapies targeting DNA methylation 
and histone modification influence the behaviour of key cancer genes is a key area for future 
research. Thus, there is the potential for selected integrins such as α2, α6 and β4 to be utilised 
as therapeutic targets, with several of these having already reached phase II in human 
clinical trials.  
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